

TABLE OF CONTENTS

| | |
|--|-----------|
| 11. Ethics, Patents and Regulatory issues | 7 |
| Introduction | 7 |
| Ethical concerns about genetic diagnosis | 7 |
| Ethical guidelines for molecular diagnostics | 8 |
| Ethical and regulatory aspects of direct-to-consumer genetic services | 9 |
| US public attitudes about genetic testing | 11 |
| Genetic testing for susceptibility to adult-onset cancer | 11 |
| Ethics of preimplantation genetic diagnosis | 12 |
| <i>Preimplantation genetic diagnosis to screen for hereditary diseases</i> | 12 |
| <i>PGD to test for susceptibility to cancer</i> | 13 |
| <i>PGD and stem cells</i> | 13 |
| Genetic research on stored tissues | 13 |
| Informed consent in clinical trials of in vitro devices | 14 |
| Concluding remarks about ethical issues | 14 |
| Insurance underwriting and gene tests | 15 |
| <i>Should genetic information be available to health insurers?</i> | 15 |
| <i>A need for the re-examination of current views</i> | 15 |
| <i>Genetic Information Nondiscrimination Act of US</i> | 16 |
| <i>Impact of the US health care reform bill on genetic testing issues</i> | 16 |
| Patents for molecular diagnostics | 16 |
| PCR patents | 16 |
| Patenting DNA sequences | 16 |
| US policy on gene patenting relevant to molecular diagnostics..... | 17 |
| The impact of disease gene patents on molecular diagnostics | 18 |
| Licensing problems associated with genetic testing | 18 |
| BRCA1 and BRCA2 gene patents | 18 |
| Role of the WHO in genetic testing standards | 19 |
| NIH's Genetic Testing Registry | 20 |
| Regulatory issues in the US | 20 |
| Assay Migration Studies for In Vitro Diagnostic Devices | 20 |
| Assessment of diagnostic accuracy | 20 |
| <i>Sensitivity and specificity</i> | 20 |
| <i>Documentation of diagnostic accuracy</i> | 21 |
| Assessment of laboratory-developed tests used by Medicare recipients..... | 22 |
| Discovery of incidental findings on genetic screening | 23 |
| Evaluation of companion diagnostics/therapeutic for cancer | 23 |
| FDA regulation of multivariate index assays | 23 |
| FDA guidance for IVDs to detect pathogens..... | 25 |
| FDA guidelines for IVDs to detect and differentiate HPV | 25 |
| FDA's Microarray Quality Control..... | 26 |
| FDA and point-of-care diagnosis | 26 |
| Genetic testing of rare disorders | 27 |
| Quality control of molecular diagnostic laboratory procedures..... | 27 |
| Quality control of point-of-care tests | 28 |
| Regulation of IVD by the FDA | 28 |
| Regulation of in vivo diagnostics by the FDA..... | 29 |
| Regulation of analytic-specific reagents | 30 |
| Regulatory aspects of FISH | 30 |
| Regulation of genetic testing | 30 |
| <i>Role of the FDA in genetic testing</i> | 30 |
| Regulatory issues concerning blood and plasma products..... | 31 |
| United States Diagnostics Standards | 31 |
| Regulation of in vitro diagnostics in the EU | 32 |
| EU regulations for testing of blood products | 32 |
| Regulation of genetic testing in EU..... | 32 |
| Evaluation of diagnostic laboratory tests in the UK | 33 |
| Pre-implantation genetic diagnosis in the UK | 33 |
| 12. Markets for Molecular Diagnostics | 35 |
| Introduction | 35 |
| Methods for study of molecular diagnostic markets | 35 |
| The overall market for diagnostic technologies | 36 |
| Molecular diagnostic markets according to technologies | 36 |
| Marketing strategies according to technologies | 37 |
| Nucleic acid isolation market | 37 |
| Market for PCR-based tests | 37 |
| <i>Markets for PCR instrumentation</i> | 37 |
| <i>Markets for real-time PCR and qRT-PCR</i> | 38 |

| | |
|---|-----------|
| <i>PCR market players</i> | 38 |
| DNA sequencing market..... | 39 |
| Cytogenetic market..... | 39 |
| <i>Market for FISH technologies</i> | 39 |
| Biochip/microarray market..... | 40 |
| Biosensor market..... | 40 |
| Nanobiotechnology for molecular diagnostics..... | 40 |
| Markets for gene expression technologies..... | 41 |
| Reagents and other disposable laboratory materials..... | 41 |
| Market for immunochemistry diagnostic..... | 41 |
| Markets for tissue diagnostics..... | 41 |
| Molecular diagnostic markets according to therapeutic areas | 41 |
| Genetic disorders..... | 42 |
| Prenatal testing..... | 43 |
| Cancer..... | 43 |
| <i>Potential markets for cancer diagnosis according to type of cancer</i> | 44 |
| Infectious diseases..... | 45 |
| <i>Sexually transmitted diseases</i> | 46 |
| <i>Hospital-acquired infections</i> | 46 |
| <i>Testing for HIV drug resistance</i> | 47 |
| <i>Potential markets for avian influenza diagnostics</i> | 47 |
| Cardiovascular diseases..... | 48 |
| Neurological disorders..... | 48 |
| Food testing..... | 48 |
| Screening of blood for transfusion..... | 49 |
| Tissue typing for transplantation..... | 49 |
| Marketing opportunities according to geographic areas | 49 |
| Unmet needs in molecular diagnostics | 50 |
| Major market trends | 50 |
| Markets according to home-brew and FDA-approved tests..... | 50 |
| Decentralization of molecular diagnostics..... | 51 |
| Point-of-care testing..... | 51 |
| Development of personalized medicine..... | 52 |
| <i>Cost of sequencing the human genome</i> | 52 |
| <i>Cost of genotyping</i> | 52 |
| <i>Marketing companion diagnostics for personalized medicine</i> | 53 |
| Development of low-cost tests..... | 53 |
| Simplification of test procedures..... | 54 |
| Increasing role of proteomics in clinical diagnostics..... | 54 |
| Forensic and legal applications..... | 55 |
| Marketing strategies | 55 |
| Role of alliances in commercialization of molecular diagnostics..... | 55 |
| <i>Acquisitions vs collaborations</i> | 56 |
| <i>Analysis of collaborations in molecular diagnostics</i> | 58 |
| <i>Licensing of the technologies</i> | 59 |
| Strategies related to laboratory facilities and technologies..... | 60 |
| Strategies relevant to the healthcare system..... | 60 |
| <i>Cost-Benefit studies</i> | 60 |
| <i>Genetic susceptibility testing</i> | 60 |
| <i>Preventive medicine strategies</i> | 61 |
| <i>Targeting treatable and common diseases</i> | 61 |
| Information/education..... | 61 |
| <i>Physician education</i> | 61 |
| <i>Patient education</i> | 62 |
| <i>European diagnostic information platform</i> | 63 |
| Regulatory strategies..... | 63 |
| Merger of in vitro and in vivo diagnostics..... | 63 |
| Integration of diagnostics with therapeutics..... | 63 |
| Diagnostic applications in clinical trials..... | 64 |
| Prospects for development of new technologies | 64 |
| Drivers for the development of molecular diagnostics..... | 64 |
| Factors slowing the development of molecular diagnostics..... | 64 |
| Government support of research relevant to molecular diagnostics..... | 65 |
| <i>Cost of sequencing the human genome</i> | 65 |
| European projects for improving molecular diagnostics..... | 67 |
| <i>European Consortium for developing new DNA analysis tools</i> | 67 |
| <i>EU project for improvement of IVD tools procedures</i> | 68 |
| <i>Genetic knowledge parks in the UK</i> | 68 |
| Molecular diagnostic opportunities in defense against bioterrorism..... | 68 |
| Molecular diagnostics for food safety..... | 69 |
| POC diagnostics for the developing countries..... | 69 |

| | |
|--|------------|
| 13. Companies involved in molecular diagnostics | 71 |
| Introduction | 71 |
| Major players in molecular diagnostics | 71 |
| Profiles of selected companies..... | 72 |
| Collaborations..... | 438 |

Tables

| | |
|--|-----|
| Table 12-1: Share of in vitro diagnostics in the global diagnostic market 2009-2019 | 36 |
| Table 12-2: Molecular diagnostics markets according to technologies from 2009-2019 | 36 |
| Table 12-3: PCR market 2009-2019 | 37 |
| Table 12-4: Molecular diagnostics markets according to applications 2009-2019..... | 41 |
| Table 12-5: Markets in 2009 for tests to screen healthy persons for genetic disorders..... | 42 |
| Table 12-6: Markets in 2009 for molecular diagnostic tests for cancer | 44 |
| Table 12-7: Molecular diagnostic markets for selected cancers 2009-2019 | 44 |
| Table 12-8: Markets value in 2009 for molecular diagnostic screening for infections..... | 45 |
| Table 12-9: Future markets for HAI diagnostics 2009-2014 | 46 |
| Table 12-10: Molecular diagnostic markets according to geographical areas 2009-2019 | 49 |
| Table 12-11: Molecular diagnostic markets according to home-brew and approved tests | 50 |
| Table 12-12: Marketing strategies for molecular diagnostics | 55 |
| Table 12-13: Takeovers of molecular diagnostic companies..... | 56 |
| Table 12-14: Advantages of the integration of diagnostics with therapeutics | 63 |
| Table 13-1: Top ten players in molecular diagnostics | 71 |
| Table 13-2: Collaborations of companies in molecular diagnostics | 438 |

Figures

| | |
|---|----|
| Figure 12-1: Unmet needs in applications of molecular diagnostics | 50 |
| Figure 12-2: Proportion of various areas in molecular diagnostic collaborations | 59 |